Arbutus Biopharma Corporation has revealed its 2025 corporate objectives and provided a financial update. The company reported cash, cash equivalents, and investments in marketable securities totaling ...
Initiating Phase 2b clinical trial in first half of 2025 after achieving a meaningful functional cure rate in cHBV patients treated with imdusiran and interferon WARMINSTER, Pa., Jan. 13, 2025 (GLOBE ...